Geron Stock Forecast, Price & News

Geron (NASDAQ:GERN) Frequently Asked Questions

Is Geron a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Geron stock.
View analyst ratings for Geron or view top-rated stocks.

How has Geron's stock been impacted by Coronavirus (COVID-19)?

Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GERN shares have increased by 16.5% and is now trading at $1.20.
View which stocks have been most impacted by COVID-19.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Geron.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.01. The biopharmaceutical company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.10 million. Geron had a negative net margin of 26,769.73% and a negative trailing twelve-month return on equity of 58.33%.
View Geron's earnings history.

What price target have analysts set for GERN?

4 Wall Street analysts have issued 12-month price objectives for Geron's stock. Their forecasts range from $4.00 to $7.00. On average, they anticipate Geron's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 358.3% from the stock's current price.
View analysts' price targets for Geron or view top-rated stocks among Wall Street analysts.

Who are Geron's key executives?

Geron's management team includes the following people:

• John A. Scarlett, Chairman, President & Chief Executive Officer
• Andrew J. Grethlein, Chief Operating Officer & Executive Vice President
• Olivia K. Bloom, Chief Financial Officer, Treasurer & Executive VP
• Aleksandra Rizo, Chief Medical Officer & Executive Vice President
• Stephen N. Rosenfield, Secretary, Chief Legal Officer & Executive VP

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron CEO John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among Geron's employees.

Who are some of Geron's key competitors?

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), United Therapeutics (UTHR), Novavax (NVAX), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of GERN's competitors.

What other stocks do shareholders of Geron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), OrganiGram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.01%).
View institutional ownership trends for Geron.

Which institutional investors are buying Geron stock?

GERN stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
View insider buying and selling activity for Geron or or view top insider-buying stocks.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.20.

How much money does Geron make?

Geron has a market capitalization of $386.34 million and generates $250 thousand in revenue each year. The biopharmaceutical company earns $-75.62 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does Geron have?

Geron employs 54 workers across the globe.

What is Geron's official website?

The official website for Geron is www.geron.com.

Where are Geron's headquarters?

Geron is headquartered at 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at [email protected], or via fax at 650-473-7750.